MDS are a group of cancers whereby the blood cells do not work properly or never formed properly. The bone marrow in yourthe body does not make enough healthy blood cells. MDS is most common in adults over the age of 60. Some people with MDS do go on to develop acute myeloid leukaemia which is cancer of the white blood cells. Drugs to improve survival rate have progressed rapidly.

We are seeking consumer input on a Cochrane protocol that aims to look at different drugs to improve the survival rate in people with higher-risk MDS.

Cochrane considers a consumer, in this case, to be someone who suffers from higher-risk myelodysplastic syndrome and is taking drugs to improve their survival rate or someone who knows a family member/friend with MDS and has experience of taking these drugs . For consumer peer review, we will ask you to complete a short form with your feedback to ensure the protocol is accessible and relevant so that it will be helpful to patients and their carers/families. Our aim is for this to be a manageable task, that does not overburden consumer reviewers.

Thank you in advance for considering!